SEC Company Response from ADMA BIOLOGICS, INC. (ADMA) (CIK 0001368514) (ADMA) — Oct 23, 2017
ADMA BIOLOGICS, INC. (ADMA) (CIK 0001368514)
Date: Oct. 23, 2017 · CIK: 0001368514 · Accession: 0001193805-17-003329
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-220910
Referenced dates: October 18, 2017
Letter
Office of the Secretary Securities and Exchange Commission Re: ADMA Biologics, Inc. Registration Statement on Form S-1 Filed October 11, 2017 File No. 333-220910
Dear Ms. Paik and Ms. Breslin:
On behalf of ADMA Biologics, Inc., a Delaware corporation (the “Company”), we respectfully submit this letter in response to the comments issued by the staff (the “Staff”) of the Securities and Exchange Commission (the “Commission”) in a letter dated October 18, 2017 (the “Letter”) regarding the Company’s Registration Statement on Form S-1 filed on October 11, 2017 (the “Registration Statement”).
Concurrently with this letter, the Company is publicly filing with the Commission Amendment No. 1 to the publicly filed Registration Statement (“Amendment No. 1”). A marked copy of Amendment No. 1 indicating changes from the Registration Statement is enclosed.
The numbering of the paragraph below corresponds to the numbering of the Staff’s comment set forth in the Letter, which, for the Staff’s convenience, has been incorporated into this response letter, marked with italicized text. Page references in this letter are to page numbers in Amendment No. 1.
Registration Statement on Form S-1 filed October 11, 2017
Underwriting, page 81
1. Based on your disclosure on the cover page and in this section, it appears you are registering a firm commitment underwritten offering of your common stock at a fixed price on a non-delayed and non-continuous basis. Given this, please explain your disclosure, "After the initial offering of the shares of Common Stock, the offering price and other selling terms may be changed by the underwriters."
Securities and Exchange Commission
October 23, 2017
Page Two
Response: The Company acknowledges the Staff’s comment and has revised page 81 of Amendment No. 1 to clarify the terms of the Company’s proposed fixed price, non-delayed, non-continuous offering.
The Company appreciates the Staff's attention to the review of the Registration Statement. Please contact the undersigned at (973) 520-2555 if you have any questions regarding the foregoing.
Very truly yours,
DLA Piper LLP (US)
Show Raw Text
CORRESP
1
filename1.htm
DLA Piper LLP (US)
51 John F. Kennedy Parkway, Suite 120
Short Hills, New Jersey 07078-2704
www.dlapiper.com
David C. Schwartz
david.schwartz@dlapiper.com
T 973.520.2555
F 973.520.2575
Partners Responsible for Short Hills Office:
Andrew P. Gilbert
Michael E. Helmer
October 23, 2017
Via UPS Overnight
Office of the Secretary
Room 10915
Mail Stop 1090
Securities and Exchange Commission
100 F Street, NE
Washington, DC 20549-1090
Re:
ADMA Biologics, Inc.
Registration Statement on Form S-1
Filed October 11, 2017
File No. 333-220910
Dear Ms. Paik and Ms. Breslin:
On behalf of ADMA Biologics,
Inc., a Delaware corporation (the “Company”), we respectfully submit this letter in response to the comments
issued by the staff (the “Staff”) of the Securities and Exchange Commission (the “Commission”)
in a letter dated October 18, 2017 (the “Letter”) regarding the Company’s Registration Statement
on Form S-1 filed on October 11, 2017 (the “Registration Statement”).
Concurrently with this
letter, the Company is publicly filing with the Commission Amendment No. 1 to the publicly filed Registration Statement (“Amendment
No. 1”). A marked copy of Amendment No. 1 indicating changes from the Registration Statement is enclosed.
The numbering of the
paragraph below corresponds to the numbering of the Staff’s comment set forth in the Letter, which, for the Staff’s
convenience, has been incorporated into this response letter, marked with italicized text. Page references in this letter are to
page numbers in Amendment No. 1.
Registration Statement on Form S-1 filed
October 11, 2017
Underwriting, page 81
1. Based on your disclosure on the cover page and in this section, it appears you are registering
a firm commitment underwritten offering of your common stock at a fixed price on a non-delayed and non-continuous basis. Given
this, please explain your disclosure, "After the initial offering of the shares of Common Stock, the offering price and other
selling terms may be changed by the underwriters."
Securities and Exchange Commission
October 23, 2017
Page Two
Response: The Company acknowledges the Staff’s comment and
has revised page 81 of Amendment No. 1 to clarify the terms of the Company’s
proposed fixed price, non-delayed, non-continuous offering.
The Company appreciates
the Staff's attention to the review of the Registration Statement. Please contact the undersigned at (973) 520-2555 if you have
any questions regarding the foregoing.
Very truly yours,
DLA Piper LLP (US)
By:
/s/ David C. Schwartz, Esq.
David C. Schwartz, Esq.
cc: Adam S. Grossman
President and Chief Executive Officer, ADMA Biologics, Inc.